Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;41(10):e15377.
doi: 10.1111/dme.15377. Epub 2024 Jun 9.

Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial

Ruth Frampton  1   2   3   4 , Jennifer R Snaith  1   2   3 , Samantha Hocking  5 , Jane Holmes-Walker  6 , Nicholas Olsen  7 , Jerry R Greenfield  1   2   3
Affiliations

Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial

Ruth Frampton et al. Diabet Med. 2024 Oct.

Abstract

Background: Premature cardiovascular disease is the leading cause of death in people living with type 1 diabetes. Therapies are urgently needed to address cardiovascular risk in this group. Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, has been shown to reduce cardiovascular events and improve weight and glycaemia in type 2 diabetes. Semaglutide may offer cardioprotective and metabolic benefits in type 1 diabetes.

Methods: We will study 60 adults aged 25-70 years with type 1 diabetes of duration at least 2 years, body mass index ≥25 kg/m2, HbA1c ≥7% and at least one cardiovascular risk factor (microalbuminuria, hypertension or anti-hypertensive treatment, hyperlipidemia or lipid lowering therapy, current smoking). Participants will receive semaglutide up to 1.0 mg weekly or matched placebo for 26 weeks. The primary outcome is carotid femoral pulse wave velocity, a measure of arterial stiffness, as a surrogate marker of cardiovascular risk. Potential mechanisms for metabolic changes will be explored including change in insulin sensitivity determined by hyperinsulinaemic-euglycaemic clamp; and incretin and pancreatic hormone action measured during mixed meal tolerance test.

Conclusion: The REducing cardiometabolic risk with SEmaglutide in Type 1 diabetes study will investigate whether semaglutide, a long acting glucagon-like peptide receptor agonist, can improve markers of cardiometabolic health in T1D. Underlying mechanisms predicting response, including insulin resistance and incretin hormone status, will also be explored.

Keywords: cardiometabolic risk; insulin resistance; metabolism; semaglutide; type 1 diabetes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407‐1418. doi:10.1056/NEJMoa1608664
    1. Harding JL, Shaw JE, Peeters A, Guiver T, Davidson S, Magliano DJ. Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997–2010. Diabetes Care. 2014;37(9):2579‐2586. doi:10.2337/dc14-0096
    1. Schauer IE, Snell‐Bergeon JK, Bergman BC, et al. Insulin resistance, defective insulin‐mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes. 2011;60(1):306‐314. doi:10.2337/db10-0328
    1. Gregory JM, Cherrington AD, Moore DJ. The peripheral peril: injected insulin induces insulin insensitivity in type 1 diabetes. Diabetes. 2020;69(5):837‐847.
    1. Snaith JR, Holmes‐Walker DJ, Greenfield JR. Reducing type 1 diabetes mortality: role for adjunctive therapies? Trends Endocrinol Metab. 2020;31(2):150‐164. doi:10.1016/j.tem.2019.11.007

Publication types

LinkOut - more resources